Avalo Therapeutics Total Liabilities

Avalo Therapeutics (AVTX) currently reports a total liabilities of $32M as of March 2026. That compares with $16M in the prior-year period — up 98.4% year over year. Use the charts on this page to explore Avalo Therapeutics's total liabilities history and peer comparisons.

Avalo Therapeutics's total liabilities increased from $16M to $32M — a 98.4% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Avalo Therapeutics reported $32M in total liabilities as of March 2026. That compares with $16M in the prior-year period — up 98.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $32M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Avalo Therapeutics, and consider following AVTX for alerts when major investors trade the stock.

Avalo Therapeutics is classified in the Healthcare sector. On total liabilities, it currently shows $32M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AVTX with unrelated industries.